Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maria Di Pietrantonio"'
Autor:
Maria Di Pietrantonio, Lucia Brescini, Jennifer Candi, Morroni Gianluca, Francesco Pallotta, Sara Mazzanti, Paolo Mantini, Bianca Candelaresi, Silvia Olivieri, Francesco Ginevri, Giulia Cesaretti, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Elisabetta Cerutti, Oriana Simonetti, Oscar Cirioni, Marcello Tavio, Andrea Giacometti, Francesco Barchiesi
Publikováno v:
Antibiotics, Vol 11, Iss 3, p 321 (2022)
Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative inf
Externí odkaz:
https://doaj.org/article/8b7095e7187d4585ac567d91cb8776d9
Autor:
Lucia Brescini, Filippo Della Martera, Gianluca Morroni, Sara Mazzanti, Maria Di Pietrantonio, Paolo Mantini, Bianca Candelaresi, Francesco Pallotta, Silvia Olivieri, Valentina Iencinella, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Salvatore Veccia, Oscar Cirioni, Marcello Tavio, Andrea Giacometti
Publikováno v:
Antibiotics, Vol 10, Iss 9, p 1129 (2021)
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalb
Externí odkaz:
https://doaj.org/article/f27076b47da4445e9f6683e0c8b370cc
Autor:
Emanuele Cocci, Filippo Della Martera, Francesco Pallotta, Andrea Giacometti, Valentina Iencinella, Silvia Olivieri, Bianca Candelaresi, Sara Mazzanti, Rosaria G. Polo, Marcello Tavio, Sefora Castelletti, Salvatore Veccia, Lucia Brescini, Gianluca Morroni, Maria Di Pietrantonio, Paolo Mantini, Oscar Cirioni
Publikováno v:
Antibiotics, Vol 10, Iss 1129, p 1129 (2021)
Antibiotics
Volume 10
Issue 9
Antibiotics
Volume 10
Issue 9
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3384c1505a49aaff406340a4b3e25e8c
https://www.mdpi.com/2079-6382/10/9/1129
https://www.mdpi.com/2079-6382/10/9/1129
Autor:
Lucia Brescini, Gianluca Svegliati Baroni, Alessandra Riva, Gianluca Morroni, Marco Tomasetti, Maria Di Pietrantonio, Alessio Ortolani, Alessandro Fiorentini, S. Gemini, Sefora Castelletti
Publikováno v:
Hepatitis Monthly. 19
The recurrence of HCV infection after liver transplantation was the main cause of mortality and loss of graft in transplanted patients until the use of direct-acting antivirals (DAAs). We performed a monocentric retrospective study from November 2014
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9297d46c05a90a2c5e1b0846981003ac
https://doi.org/10.5812/hepatmon.90624
https://doi.org/10.5812/hepatmon.90624